Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes.
The “Metabolic Syndrome Industry Forecast” looks at past sales and reviews total world Metabolic Syndrome sales in 2022, providing a comprehensive analysis by region and market sector of projected Metabolic Syndrome sales for 2023 through 2029. With Metabolic Syndrome sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Metabolic Syndrome industry.
This Insight Report provides a comprehensive analysis of the global Metabolic Syndrome landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Metabolic Syndrome portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Metabolic Syndrome market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Metabolic Syndrome and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Metabolic Syndrome.
The global Metabolic Syndrome market size is projected to grow from US$ 23370 million in 2022 to US$ 33530 million in 2029; it is expected to grow at a CAGR of 5.3% from 2023 to 2029.
One of the upcoming trends gaining traction in the market is the increasing focus on oral insulin therapies. Till now, insulin injections were mostly administered through subcutaneous tissues, but this route of application is associated with risk of infection and hypersensitivity reactions, emboli, high cost, and injection site pain. Also, several needle-phobic individuals hesitate to adopt this route of administration. This paved the way for extensive research in the development of oral insulin. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Moreover, oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.
This report presents a comprehensive overview, market shares, and growth opportunities of Metabolic Syndrome market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Diabetes
Obesity
Hypercholesterolemia
Lysosomal storage diseases
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lily
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
nAmgen
Amicus Therapeutics
Arbutus Biopharma
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Metabolic Syndrome Market Size 2018-2029
2.1.2 Metabolic Syndrome Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Metabolic Syndrome Segment by Type
2.2.1 Diabetes
2.2.2 Obesity
2.2.3 Hypercholesterolemia
2.2.4 Lysosomal storage diseases
2.3 Metabolic Syndrome Market Size by Type
2.3.1 Metabolic Syndrome Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Metabolic Syndrome Market Size Market Share by Type (2018-2023)
2.4 Metabolic Syndrome Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Metabolic Syndrome Market Size by Application
2.5.1 Metabolic Syndrome Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Metabolic Syndrome Market Size Market Share by Application (2018-2023)
3 Metabolic Syndrome Market Size by Player
3.1 Metabolic Syndrome Market Size Market Share by Players
3.1.1 Global Metabolic Syndrome Revenue by Players (2018-2023)
3.1.2 Global Metabolic Syndrome Revenue Market Share by Players (2018-2023)
3.2 Global Metabolic Syndrome Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Metabolic Syndrome by Regions
4.1 Metabolic Syndrome Market Size by Regions (2018-2023)
4.2 Americas Metabolic Syndrome Market Size Growth (2018-2023)
4.3 APAC Metabolic Syndrome Market Size Growth (2018-2023)
4.4 Europe Metabolic Syndrome Market Size Growth (2018-2023)
4.5 Middle East & Africa Metabolic Syndrome Market Size Growth (2018-2023)
5 Americas
5.1 Americas Metabolic Syndrome Market Size by Country (2018-2023)
5.2 Americas Metabolic Syndrome Market Size by Type (2018-2023)
5.3 Americas Metabolic Syndrome Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Metabolic Syndrome Market Size by Region (2018-2023)
6.2 APAC Metabolic Syndrome Market Size by Type (2018-2023)
6.3 APAC Metabolic Syndrome Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Metabolic Syndrome by Country (2018-2023)
7.2 Europe Metabolic Syndrome Market Size by Type (2018-2023)
7.3 Europe Metabolic Syndrome Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Metabolic Syndrome by Region (2018-2023)
8.2 Middle East & Africa Metabolic Syndrome Market Size by Type (2018-2023)
8.3 Middle East & Africa Metabolic Syndrome Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Metabolic Syndrome Market Forecast
10.1 Global Metabolic Syndrome Forecast by Regions (2024-2029)
10.1.1 Global Metabolic Syndrome Forecast by Regions (2024-2029)
10.1.2 Americas Metabolic Syndrome Forecast
10.1.3 APAC Metabolic Syndrome Forecast
10.1.4 Europe Metabolic Syndrome Forecast
10.1.5 Middle East & Africa Metabolic Syndrome Forecast
10.2 Americas Metabolic Syndrome Forecast by Country (2024-2029)
10.2.1 United States Metabolic Syndrome Market Forecast
10.2.2 Canada Metabolic Syndrome Market Forecast
10.2.3 Mexico Metabolic Syndrome Market Forecast
10.2.4 Brazil Metabolic Syndrome Market Forecast
10.3 APAC Metabolic Syndrome Forecast by Region (2024-2029)
10.3.1 China Metabolic Syndrome Market Forecast
10.3.2 Japan Metabolic Syndrome Market Forecast
10.3.3 Korea Metabolic Syndrome Market Forecast
10.3.4 Southeast Asia Metabolic Syndrome Market Forecast
10.3.5 India Metabolic Syndrome Market Forecast
10.3.6 Australia Metabolic Syndrome Market Forecast
10.4 Europe Metabolic Syndrome Forecast by Country (2024-2029)
10.4.1 Germany Metabolic Syndrome Market Forecast
10.4.2 France Metabolic Syndrome Market Forecast
10.4.3 UK Metabolic Syndrome Market Forecast
10.4.4 Italy Metabolic Syndrome Market Forecast
10.4.5 Russia Metabolic Syndrome Market Forecast
10.5 Middle East & Africa Metabolic Syndrome Forecast by Region (2024-2029)
10.5.1 Egypt Metabolic Syndrome Market Forecast
10.5.2 South Africa Metabolic Syndrome Market Forecast
10.5.3 Israel Metabolic Syndrome Market Forecast
10.5.4 Turkey Metabolic Syndrome Market Forecast
10.5.5 GCC Countries Metabolic Syndrome Market Forecast
10.6 Global Metabolic Syndrome Forecast by Type (2024-2029)
10.7 Global Metabolic Syndrome Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Metabolic Syndrome Product Offered
11.1.3 Novo Nordisk Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Metabolic Syndrome Product Offered
11.2.3 Sanofi Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Sanofi Main Business Overview
11.2.5 Sanofi Latest Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck Metabolic Syndrome Product Offered
11.3.3 Merck Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Merck Main Business Overview
11.3.5 Merck Latest Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Metabolic Syndrome Product Offered
11.4.3 AstraZeneca Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 AstraZeneca Main Business Overview
11.4.5 AstraZeneca Latest Developments
11.5 Eli Lily
11.5.1 Eli Lily Company Information
11.5.2 Eli Lily Metabolic Syndrome Product Offered
11.5.3 Eli Lily Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Eli Lily Main Business Overview
11.5.5 Eli Lily Latest Developments
11.6 AbbVie
11.6.1 AbbVie Company Information
11.6.2 AbbVie Metabolic Syndrome Product Offered
11.6.3 AbbVie Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 AbbVie Main Business Overview
11.6.5 AbbVie Latest Developments
11.7 Actelion Pharmaceuticals
11.7.1 Actelion Pharmaceuticals Company Information
11.7.2 Actelion Pharmaceuticals Metabolic Syndrome Product Offered
11.7.3 Actelion Pharmaceuticals Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Actelion Pharmaceuticals Main Business Overview
11.7.5 Actelion Pharmaceuticals Latest Developments
11.8 Adocia
11.8.1 Adocia Company Information
11.8.2 Adocia Metabolic Syndrome Product Offered
11.8.3 Adocia Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Adocia Main Business Overview
11.8.5 Adocia Latest Developments
11.9 Aegerion Pharmaceuticals
11.9.1 Aegerion Pharmaceuticals Company Information
11.9.2 Aegerion Pharmaceuticals Metabolic Syndrome Product Offered
11.9.3 Aegerion Pharmaceuticals Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Aegerion Pharmaceuticals Main Business Overview
11.9.5 Aegerion Pharmaceuticals Latest Developments
11.10 Akros Pharma
11.10.1 Akros Pharma Company Information
11.10.2 Akros Pharma Metabolic Syndrome Product Offered
11.10.3 Akros Pharma Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Akros Pharma Main Business Overview
11.10.5 Akros Pharma Latest Developments
11.11 Alnylam Pharmaceuticals
11.11.1 Alnylam Pharmaceuticals Company Information
11.11.2 Alnylam Pharmaceuticals Metabolic Syndrome Product Offered
11.11.3 Alnylam Pharmaceuticals Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Alnylam Pharmaceuticals Main Business Overview
11.11.5 Alnylam Pharmaceuticals Latest Developments
11.12 Amarin
11.12.1 Amarin Company Information
11.12.2 Amarin Metabolic Syndrome Product Offered
11.12.3 Amarin Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Amarin Main Business Overview
11.12.5 Amarin Latest Developments
11.13 nAmgen
11.13.1 nAmgen Company Information
11.13.2 nAmgen Metabolic Syndrome Product Offered
11.13.3 nAmgen Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 nAmgen Main Business Overview
11.13.5 nAmgen Latest Developments
11.14 Amicus Therapeutics
11.14.1 Amicus Therapeutics Company Information
11.14.2 Amicus Therapeutics Metabolic Syndrome Product Offered
11.14.3 Amicus Therapeutics Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Amicus Therapeutics Main Business Overview
11.14.5 Amicus Therapeutics Latest Developments
11.15 Arbutus Biopharma
11.15.1 Arbutus Biopharma Company Information
11.15.2 Arbutus Biopharma Metabolic Syndrome Product Offered
11.15.3 Arbutus Biopharma Metabolic Syndrome Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Arbutus Biopharma Main Business Overview
11.15.5 Arbutus Biopharma Latest Developments
12 Research Findings and Conclusion
*If Applicable.